Abstract

The primary goal of radioiodine therapy is to achieve the ablation of residual thyroid cancer tissue following total thyroidectomy in the treatment of thyroid cancer. Due to its ease of application, the fixed-dose method is the most commonly used approach in clinical practice. In patient-specific dosimetry, it is essential to understand the dose-response relationship prior to treatment to determine the minimum effective and maximum safe absorbed doses, tumor radiation response, and healthy tissue toxicity for each patient. The radioiodine dose required for residual tissue ablation is known to be 300 Gy. During dosimetry procedures, the amount of iodine-131 activity necessary to deliver this dose is calculated.